Clinical Trial Update: Sorafenib in Urothelium Cancer of Bladder [Phase 2]

View source ↗

Summary

The Phase 2 trial of sorafenib for bladder cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Association of Urologic Oncology (AUO) | Conditions: Bladder Cancer | Phase 2 | Status: TERMINATED